The Use of CFTR Protein Modifiers (Kaftrio/Kalydeco) at the Pediatric Clinic of the Clinical Center University of Sarajevo.

Autor: Radoš-Kosić, Tanja¹, Selimović, Amina² aminaselimovic778@gmail.com

Publikováno v: Medical Journal / Medicinski Žurnal. Jul/Sep2024, Vol. 30 Issue 3, p99-101. 3p.

Putting Kaftrio into perspective: a test case for fair and open priority setting.

Autor: Brendbekken A; Bergen Centre for Ethics and Priority Setting in Health, University of Bergen, 5009 Bergen, Norway., Bhopal A; Bergen Centre for Ethics and Priority Setting in Health, University of Bergen, 5009 Bergen, Norway.

Publikováno v: BMJ (Clinical research ed.) [BMJ] 2024 Jan 29; Vol. 384, pp. q182. Date of Electronic Publication: 2024 Jan 29.

Rashs cutanés sous KAFTRIO/KALYDECO

Autor: Quatremare, M., Tetart, F., Boulay, C., Montastruc, F., Revol, B., Pramil, S., Morisse Pradier, H., Marguet, C., Couderc, L.

Publikováno v: In Revue Française d'Allergologie April 2024 64 Supplement

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®.

Autor: Purkayastha, Debanjali¹ (AUTHOR), Agtarap, Kyla¹ (AUTHOR), Wong, Kristy¹ (AUTHOR), Pereira, Onella² (AUTHOR), Co, Jannie³ (AUTHOR), Pakhale, Smita⁴ (AUTHOR), Kanji, Salmaan^1,5 (AUTHOR) skanji@toh.ca

Publikováno v: Journal of Cystic Fibrosis. May2023, Vol. 22 Issue 3, p478-483. 6p.